<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03285568</url>
  </required_header>
  <id_info>
    <org_study_id>16082509</org_study_id>
    <nct_id>NCT03285568</nct_id>
  </id_info>
  <brief_title>Patterns of Prescribing and Monitoring of Palbociclib</brief_title>
  <official_title>Patterns of Prescribing and Monitoring of Palbociclib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if patients with ER+, human epidermal growth factor
      2 negative (HER2-), advanced breast cancer are receiving dosing adjustments and monitoring
      based on manufacturer recommendations at a tertiary academic medical center.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 3, 2015</start_date>
  <completion_date type="Actual">December 30, 2016</completion_date>
  <primary_completion_date type="Actual">December 30, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>identify the proportion of patients who were maintained on a palbociclib dose according to the package insert recommendations</measure>
    <time_frame>2/3/2015-12/30/2016</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of patients who required dose adjustment for hematologic toxicities</measure>
    <time_frame>2/3/2015-12/30/2016</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients who experienced neutropenia</measure>
    <time_frame>2/3/2015-12/30/2016</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of therapy</measure>
    <time_frame>2/3/2015-12/30/2016</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>2/3/2015-12/30/2016</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percent adherence to manufacturer monitoring recommendations</measure>
    <time_frame>2/3/2015-12/30/2016</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">67</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Advanced Breast Cancer</condition>
  <condition>Estrogen Receptor-positive Breast Cancer</condition>
  <condition>Human Epidermal Growth Factor 2 Negative Carcinoma of Breast</condition>
  <arm_group>
    <arm_group_label>Palbociclib</arm_group_label>
    <description>women at least 18 years old, with ER+, HER2- advanced breast cancer, and were receiving palbociclib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Observe patients receiving palbociclib for dose adjustment and lab monitoring</description>
    <arm_group_label>Palbociclib</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients seen at RUMC
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women at least 18 years old

          -  ER+, HER2- advanced breast cancer

          -  receiving palbociclib

        Exclusion Criteria:

          -  brain metastases

          -  on palbociclib clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2017</study_first_submitted>
  <study_first_submitted_qc>September 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2017</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

